AbbVie touts phase 3 results for Epkinly in 2L large B-cell lymphoma
Seeking Alpha ·
AbbVie ( ABBV ) said that its experimental T-cell engaging bispecific antibody Epkinly (epcoritamab) in combination with Revlimid (lenalidomide) led to better progression-free survival in large B-cell lymphoma patients who had failed on at least one prior therapy compared to those on a regimen
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
439 participants
Related News
- Review & Preview: 52,000
- Persian Gulf producers keep pushing oil, LNG loadings despite ship attacks
- Concentrix targets $630M-$650M FY2026 adjusted free cash flow while aiming to surpass $120M iX Suite ARR
- Digital-Asset Treasury Companies Continue to Accumulate Crypto. But Are Any of Them Worth Buying?
- Why Copart Stock Stumbled Today
- Australia sues Amazon unit over alleged breach via Prime Video ads